A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia
- First Posted Date
- 2013-11-27
- Last Posted Date
- 2020-01-31
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 291
- Registration Number
- NCT01995838
A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults
- Conditions
- Interventions
- First Posted Date
- 2013-11-19
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 344
- Registration Number
- NCT01987427
- Locations
- ๐บ๐ธ
Scripps Clinical Research Center, La Jolla, California, United States
๐บ๐ธRadiant Research - Dallas, Dallas, Texas, United States
๐บ๐ธNational Clinical Research - Norfolk, Norfolk, Virginia, United States
Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
- First Posted Date
- 2013-11-05
- Last Posted Date
- 2018-02-27
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 204
- Registration Number
- NCT01976104
An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects
- First Posted Date
- 2013-11-05
- Last Posted Date
- 2016-01-08
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 113
- Registration Number
- NCT01975636
- Locations
- ๐บ๐ธ
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States
๐บ๐ธCovance Laboratories, Madison, Wisconsin, United States
Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure
- First Posted Date
- 2013-10-30
- Last Posted Date
- 2018-02-27
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 231
- Registration Number
- NCT01972529
Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung
- Conditions
- Interventions
- First Posted Date
- 2013-06-13
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT01877083
- Locations
- ๐ธ๐ฌ
National University Hospital, Singapore, Singapore
๐ธ๐ฌNational Cancer Center Hospital, Singapore, Singapore
๐จ๐ณVeterans General Hospital Taipei, Taipei, Taiwan
A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 112
- Registration Number
- NCT01871727
- Locations
- ๐บ๐ธ
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
๐บ๐ธRush University Medical Center, Chicago, Illinois, United States
๐บ๐ธYale University Cancer Center, New Haven, Connecticut, United States
An Extended Access Program for Perampanel
- Conditions
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Eisai Inc.
- Registration Number
- NCT01871233
- Locations
- ๐ฆ๐บ
St Vincent's Hospital Melbourne, Fitzroy, Australia
๐จ๐ฟFakultni Nemocnice U Sv. Anny V Brne, Brno, Czechia
๐ฆ๐บRoyal Melbourne Hospital, Parkville, Australia
A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM)
- First Posted Date
- 2013-04-12
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT01830868
A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)
- First Posted Date
- 2013-04-12
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 254
- Registration Number
- NCT01830400